Information Provided By: 
Fly News Breaks for July 8, 2016
JUNO, BLUE
Jul 8, 2016 | 07:28 EDT
Jefferies analyst Gena Wang believes the clinical hold placed on Juno Therapeutics' (JUNO) JCAR015 trial has a limited impact on bluebird bio (BLUE). bluebird's bb2121 CART program has differences in construct, vector, target/disease and dosing regimen, Wang tells investors in a research note. Further, she believes the Street consensus contains minimal valuation for the bb2121 program. Wang keeps a Buy rating on the shares with an $80 price target.
News For BLUE;JUNO From the Last 2 Days
